NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Since today's MIA manufacturing certificate puts NWBO on the road to commercial approval in the U.K by 8/1/23, and in the U.S. by 12/31/23 , let's list what might be in an S-1 to get institutional ownership up from the current zero. None of these top biotech funds have any ownership of NWBO.( https://www.fiercebiotech.com/special-report/top-7-life-sciences-public-investors). By '29, FCF should be $3.5 billion from $ 4 billion in revenues.


Therefore, let's speculate on what could be in the S-1:

1) MAA filing by 4/1/23.

2) NICE commitment letter for patient cost coverage by 6/1/23.

3) Full U.K. commercial approval by 8/1/23.

4) Full FDA approval by 12/31/23.

5) Stock priced at $4.00 .

6) 250 million shares for 5 institutions.250 million shares for retail.$ 2 billion in proceeds.

7) New COO announced.

8) Announced CRL global manufacturing agreement.

9) Uplist to NYSE when the S-1 goes effective.

10) Major bracket firm investment banker on board.

11) Absent the short side activities of the past 10- year , DC VAX L could have come to market 5 years ago. 3 million cancer deaths have occurred during the last 5 years. DC VAX L could gave prevented 5%, or 150,000 . At a damage award of $ 5 million per patient , the total damage award is $750 billion. Settlement: Citadel et al pay $ 5 billion to NWBO; $ 5 billion to cancer research.


12) As to criminal charges (murder 1), federal agencies sue Citadel et al principals .Since they are bankrupted by the civil suit settlement , the penalty becomes 10 years in jail.


https://www.webmd.com/cancer/how-many-cancer-deaths-per-year



https://www.fiercebiotech.com/special-report/top-7-life-sciences-public-investors

NWBO
4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
March 20, 2023
We are pleased to send you our most recent press release issued today, announcing an important milestone: the MIA commercial manufacturing license has been approved by the Medical and Healthcare Products Regulatory Agency (MHRA) for our plant in Sawston, UK. Please also note that under this license, cellular products manufactured in this facility may be exported globally.

Best,


Dave Innes
VP, Investor Relations
Northwest Bio?therapeutics, Inc.


For Immediate Release on March 20, 2023


Northwest Biotherapeutics and Advent BioServices Announce

Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

One of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products;

Allows Global Delivery of the Products


BETHESDA, MD, March 20, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and Advent BioServices, a leading contract development and manufacturing organization (CDMO) based in the UK, jointly announce that a MIA license has been approved and issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at the GMP facility in Sawston, U.K.

This MIA is one of the first licenses for commercial manufacturing of cell therapy products in the U.K. To the companies’ knowledge, there are only two other such licenses, one of which was just granted as well.

This license is the culmination of more than 3 years’ work, including development of the facility, the teams of specialized personnel, the Standard Operating Procedures (SOPs) and systems, well over 1,650 regulatory documents, and a successful operating history under the initial manufacturing licenses previously obtained to produce cell therapies in the Sawston facility for clinical trials and compassionate use. All of this work was carried out by Advent BioServices under contract with NW Bio.

Under this commercial manufacturing license, cell therapy products manufactured in the Sawston facility may be exported globally. Products (e.g., immune cells) may also be imported into the U.K. for production or release of cell therapy products under the facility’s licenses.

Linda Powers, CEO of NW Bio, commented “We are very excited to reach this major milestone, as it is an essential step towards submission of our application for regulatory approval of our lead product, DCVax®-L. It is especially exciting to be able to operate globally from this base in the U.K.”

Dr. Mike Scott, President of Advent BioServices, commented “It is always challenging to be one of the trailblazers. The field of personalised cell-based immunotherapy is rapidly evolving and we are collectively navigating our way through the regulatory landscape. We are therefore thrilled that the extensive preparatory work undertaken by our skilled and dedicated team has met the extremely high standards set for this commercial level of manufacturing license.”

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” This Phase III trial has been completed, and the results have been presented in scientific meetings and published in JAMA Oncology. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.


About Advent BioServices

Advent BioServices is a contract development and manufacturing organization (CDMO) based in Sawston, U.K. The Company operates the 88,000 square foot GMP facility in Sawston, which includes a large, HTA licensed, cryostorage facility capable of storing several million vials of tissues and cells, and includes capabilities for all stages of cell therapy development and production. During the past three-plus years, the Company has recruited staff members with a wide spectrum of specialist skills in the cell therapy space. The Process Development and QC teams provide significant expertise in complex assay development, GMP manufacturing, product release and GMP-related monitoring which has underpinned the work leading to MHRA licensing for commercial manufacturing, as well as the prior licenses for manufacturing for clinical trials and compassionate use (Specials).


CONTACTS
Dave Innes
804-513-4758 [e-mail]
Les Goldman
240-234-0059 [e-mail]